



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Ranju Ralhan

Serial No.

09/749.778

Art Unit : 1634

Filed

For

December 28, 2000

Examiner: Sally A. SAKELARIS

Polymorphism in p21 waf1/cip1 Gene. Association with Human Cancer and uses Related Thereto

DECLARATION UNDER 37 CFR 1.132

TO OVERCOME REJECTION UNDER 35 U.S.C. § 103 (a)

Commissioner for Patents Washington DC 20231

Sir,

Declaration of Ranju Ralhan

I, Ranju Ralhan, declare as follows:

I am the sole inventor of the subject matter described and claimed in the above-identified application.

I am a co-author of a report in the publication Clinical Cancer Research, Vol. 6,2440-2447, 7/2000, the report being entitled "Association Between Polymorphism in p21 waf1/ cip1 Cyclin Dependent Kinase Inhibitor Gene and Human Oral Cancer". In an office Action mailed November 6, 2002 relative to the above-identified application, this publication forms the basis for a rejection of claims 2-7 under 35 U.S.C. § 103 (a).

I am the sole inventor of the subject matter which is disclosed in said publication and disclosed and claimed in the above-identified application.

contd.

The other author of the publication, Sandhya Agarwal was working under my direction, supervision and control and is not co-inventor of the subject matter described in the publication. This work was supported by research grant from Indo French centre for Promotion of Advanced Research, hence the French Collaborator Dr. Bohdan Wasylyk is a co-author in the publication. Dr. Anurag Srivastava, Professor, Department of Surgical Disciplines provided the clinical specimens used in the publication. Dr. Meera Mathur, Professor of Patholoy, helped with the histopathology part of the work in the publication. Hence, they are not co-inventors of the subject matter in the publication.

I declare that all statements made herein of my own knowledge are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

January 27, 2003

Date

Respectfully Submitted

Raniu Ralhan

ECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

:

Ranju Ralhan

Serial No.

_

09/749.778

Art Unit : 1634

Filed

December 28, 2000

Examiner: Sally A. SAKELARIS

For

Polymorphism in p21 waf1/cip1 Gene. Association with Human

Cancer and uses Related Thereto

DECLARATION UNDER 37 CFR 1.132
TO OVERCOME REJECTION UNDER 35 U.S.C. § 102 (a)

Commissioner for Patents Washington DC 20231

Sir,

Declaration of Ranju Ralhan

I, Ranju Ralhan, declare as follows:

I am the sole inventor of the subject matter described and claimed in the above-identified application.

I am a co-author of a report in the publication Oncogene, (2000 Jan 20) 19 (3) 323-8, the repot being entitled "Novel Polymorphism iin p21 waff/lip1 Cyclin Dependent Kinase Inhibitor Gene: Association with Human Esophageal Cancer". In an office Action mailed November 6, 2002 relative to the above-identified application, this publication forms the basis for a rejection of claims 2-7 under 35 U.S.C. § 102 (a).

I am the sole inventor of the subject matter which is disclosed in said publication and disclosed and claimed in the above-identified application.

The other authors of the publication, Rimple Bahl, Sonia Arora and Neera Nath were working under my direction, supervision and control and are not co-inventors of the subject matter described in the publication. Dr. Meera Mathur Professor in Department of Pathology was a collaborator in this publication who helped us with the histopathology part of the work in the publication. Dr. Nootan K. Shukla, Additional Professor, Surgical Oncology Unit, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences provided the clinical tissue specimens used in the publication. Hence, they are not co-inventors of the subject matter

I declare that all statements made herein of my own knowledge are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

January 27, 2003 Date Respectfully Submitted

Ranju Ralhan